BIIB
BIOGEN INC.
NASDAQ · Healthcare · Drug Manufacturers - General · US
$252.71
+1.52%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 10.3B | 9.8B | 9.7B | 9.8B | 10.2B |
| Cost of Revenue | 3.1B | 2.9B | 2.3B | 2.5B | 2.3B |
| Gross Profit | 7.2B | 6.9B | 7.4B | 7.3B | 7.9B |
| Operating Expenses | |||||
| R&D Expense | 2.2B | 2.0B | 2.5B | 2.7B | 2.6B |
| SG&A Expense | 2.8B | 2.4B | 2.4B | 2.5B | 2.4B |
| General & Admin Expense | 1.4B | 2.4B | 2.3B | 2.4B | 2.4B |
| Selling & Marketing Expense | — | — | 66.8M | 71.4M | 54.1M |
| Other Expenses | 1.5B | 647.7M | — | — | — |
| Total Operating Expenses | 6.4B | 5.0B | 4.9B | 5.2B | 5.0B |
| Cost and Expenses | 9.5B | 7.9B | 7.2B | 7.7B | 7.3B |
| Operating Income (EBIT) | 786.9M | 1.9B | 2.5B | 2.1B | 2.9B |
| Non-Operating | |||||
| Interest Income | 109.7M | 87.8M | 67.6M | 276.5M | 89.3M |
| Interest Expense | 304.9M | 246.0M | 250.3M | 246.9M | 246.6M |
| Net Interest Income | (195.2M) | (158.2M) | (182.7M) | 29.6M | (157.3M) |
| Other Non-Op Income/Expense | (496.8M) | (476.0M) | (584.3M) | (800.5M) | 705.3M |
| Non-Operating Income (excl Interest) | 220.1M | (287.7M) | 167.8M | 215.1M | (129.4M) |
| EBT (Pre-Tax Income) | 290.1M | 1.4B | 1.9B | 1.3B | 3.6B |
| Income Tax Expense | (57.9M) | 108.1M | 273.8M | 135.3M | 632.8M |
| Bottom Line | |||||
| Net Income | 348.0M | 1.3B | 1.6B | 1.2B | 3.0B |
| Earnings from Cont. Ops | 348.0M | 1.3B | 1.6B | 1.2B | 3.0B |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 348.0M | 1.3B | 1.6B | 1.2B | 3.0B |
| Per Share | |||||
| Basic EPS | $2.36 | $8.85 | $11.20 | $8.02 | $20.97 |
| Diluted EPS | $2.34 | $8.83 | $11.19 | $7.97 | $20.87 |
| Revenue Per Share | $69.67 | $66.88 | $66.41 | $67.97 | $70.02 |
| Shares | |||||
| Basic Shares Outstanding | 147.8M | 146.7M | 145.7M | 144.7M | 145.3M |
| Diluted Shares Outstanding | 147.8M | 146.7M | 145.9M | 145.6M | 146.0M |
| Profitability Metrics | |||||
| EBITDA | 1.4B | 2.9B | 3.0B | 2.4B | 3.5B |
| D&A | 881.8M | 779.9M | 673.2M | 494.8M | 518.4M |
| EBIT | 566.8M | 2.2B | 2.3B | 1.9B | 3.0B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026